Thorough QT study of ELND 005 in volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2015
At a glance
- Drugs ELND 005 (Primary) ; Moxifloxacin
- Indications Alzheimer's disease; Bipolar disorders; Cognition disorders
- Focus Adverse reactions
- Sponsors Transition Therapeutics
- 15 Jan 2015 New trial record
- 24 Nov 2014 Results published in Transition Therapeutics media release.
- 24 Nov 2014 Results data were presented at Clinical Trials in Alzheimer's Disease conference on November 2014, according to a Transition Therapeutics media release.